Article citationsMore>>

Howell, A., Robertson, J.F.R., Albano, J.Q., Aschermannova, A., Mauriac, L., Kleeberg, U.R., Vergote, I., Erikstein, B., Webster, A. and Morris, C. (2002) Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women with Advanced Breast Cancer Progressing after Prior Endocrine Treatment. Journal of Clinical Oncology, 20, 3396-3403.
http://dx.doi.org/10.1200/JCO.2002.10.057

has been cited by the following article:

• TITLE: Antiestrogenic Compounds and Breast Cancer

  AUTHORS: Muhammad Asim, Noman Ali, Raheel Asghar, Awais Amin, Muhammad Saif Ur Rahman

  KEYWORDS: Breast Cancer, Anti-Estrogen Compounds, Bcl-2, GRP78, Caspase 8

  JOURNAL NAME: Open Access Library Journal, Vol.3 No.3, March 18, 2016

  ABSTRACT: Breast cancer is the main threat around the world. Estrogen and estrogen receptors (ER) assume a noteworthy part in breast disease movement and advancement. Breast cancer is the most pervasive disease in women, every year more than 200,000 new cases analyzed. Estrogen receptors are expressed in 70% of all the breast cancer cases, so it is an important target for the treatment of breast cancer. Anti-estrogen compounds are of significant importance since it can be used as a therapy for breast cancer. In this review we have summarized the most important anti-estrogen compounds being used for the treatment of the breast cancer and their related molecular pathways with the hope that this will enhance our understanding to these compounds.